Capricor Therapeutics, Inc. (CAPR)
Summary
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.
Capricor Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 43 | $1,183.98 | $251.98 | -$932 | -78.72% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 26,775 | $644,740 | $156,499.87 | -$488,240.13 | -75.73% |
| NA Nizar Araji National Bank Of Canada /FI/ | 11 | $261.8 | $64.46 | -$197.34 | -75.38% |
| BG Bart Gancher Intech Investment Management LLC | 17,114 | $506,907.2 | $106,705.79 | -$400,201.41 | -78.95% |
| KT Kevin Tang Tang Capital Management LLC | 3.4M | $100.74M | $19.82M | -$80.92M | -80.32% |
Capricor Therapeutics, Inc. (CAPR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Capricor Therapeutics, Inc. ever had a stock split?
Capricor Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Linda Marbán CEO | NASDAQ (CM) Exchange | 14070B309 CUSIP |
| US Country | 231 Employees | 5 Jun 2019 Last Dividend | 5 Jun 2019 Last Split | 13 Feb 2007 IPO Date |
Overview
Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm established in 2005, with its headquarters located in San Diego, California. The company is dedicated to the development of revolutionary cell and exosome-based therapeutics aimed at treating a variety of diseases that currently have unmet medical needs, with a particular focus on Duchenne Muscular Dystrophy (DMD). Through its advanced research and clinical trials, Capricor Therapeutics strives to bring innovative treatments to patients suffering from DMD and other serious conditions. The company has established several important collaborations and licensing agreements with prestigious institutions and companies, including Nippon Shinyaku Co. Ltd., National Institute of Allergy and Infectious Diseases, Johns Hopkins University, Cedars-Sinai Medical Center, and Life Technologies Corporation, to further its research and development efforts.
Products and Services
- CAP-1002
- StealthX
- CAP-2003
This allogeneic cardiac-derived cell therapy is Capricor Therapeutics’ leading candidate, specifically aimed at treating patients with late-stage Duchenne muscular dystrophy (DMD). Having completed phase 3 clinical trials, CAP-1002 represents a significant advancement in the quest for effective DMD therapies, showing promise in addressing the needs of patients suffering from this debilitating disease.
StealthX is an innovative engineered exosome-based vaccine candidate that is currently under phase 1 clinical study. This candidate is designed for a multitude of therapeutic applications, including the delivery of targeted RNA, proteins, and small molecule therapeutics. StealthX is aimed at treating or preventing a variety of diseases, showcasing Capricor’s dedication to leveraging cutting-edge science in its therapeutic development.
Currently in the pre-clinical development stage, CAP-2003 is being explored for its potential in treating trauma-related injuries and conditions. This further exemplifies Capricor Therapeutics’ commitment to expanding its portfolio of treatments and addressing a broader range of medical concerns that lack effective treatments.
Contact Information
